Abstract:Objective To quantify the changes in blood glucose, blood lipids, blood pressure, and the intima-media thickness (IMT) of large arteries in patients with new-onset type 2 diabetes mellitus who received either intensive multifactorial treatment or conventional treatment. Methods Two-hundred and ten patients with new-onset type 2 diabetes mellitus were randomly assigned to two groups: an intensive treatment group ( n =110) and a conventional treatment group ( n =100). Fasting blood glucose (FBG), glycosylated hemoglobin A1c (HbA1c), blood pressure, blood lipids [total cholesterol (TC), triglyceride (TG), low-density lipoprotein C (LDL-C), and high-density lipoprotein C (HDL-C)], and IMTs of large arteries (carotid, iliac, and femoral arteries) were determined before and at one and two years after starting treatment. The patients in the conventional treatment group received routine diabetes management in our outpatient department. Targets were established for patients in the intensive treatment group. Their blood glucose, blood lipids, and blood pressure levels were regularly monitored and therapeutic regimens were adjusted for those whose measurements did not meet the target values until all the parameters met the established targets. Within-group and between-group differences were evaluated. Results A significantly greater percentage of patients in the intensive treatment group had LDL-C levels that reached the target value one year after starting treatment than those in the conventional treatment group (52.04% vs. 33.33%, P <0.05). No significant differences were found between groups for FBG, HbA1c, blood pressure, TG, TC, or HDL-C. The percentages of patients with TG (51.02% vs. 34.48%), TC (52.04% vs. 33.33%), and LDL-C (61.22% vs. 43.67%) who met the respective target values in the intensive treatment group were all significantly higher than the corresponding percentages in the conventional treatment group two years after starting treatment ( P <0.05). There were no significant differences in the percentages of patients with FBG, HbA1c, and blood pressure values meeting the respective targets between the groups at the two-year follow-up. One year after starting treatment, the LDL-C level, diastolic blood pressure (DBP), and the IMTs of the femoral and iliac arteries of the intensive treatment group were significantly lower compared to those of the conventional treatment group ( P <0.05), although there was no significant difference in other metabolic parameters. Two years after starting treatment, the TC, LDL-C, blood pressure [systolic blood pressure (SBP) and DBP], and the IMTs of the carotid and femoral arteries of the intensive treatment group were significantly lower than those of the conventional treatment group ( P <0.05). No significant differences in other metabolic parameters existed between the two groups two years after starting treatment. Conclusions Early comprehensive and intensive treatment of type 2 diabetes mellitus can delay or even reverse the increase in IMT of large arteries. Lowering blood pressure and blood lipid regulation in patients with type 2 diabetes mellitus have great significance in decreasing the risk of diabetes-related macrovascular lesions.

Individualized intensive insulin therapy of diabetes: Not only the goal, but also the time

Changes of Blood Pressure,blood Glucose and Blood Lipids Levels after Intensive Treatment in Incipient Diabetes II Patients

Effect of Intensive Multifactorial Treatment on the Intima-Media Thickness of Large Arteries in Patients with New-Onset Type 2 Diabetes Mellitus

Current Role of Short-Term Intensive Insulin Strategies in Newly Diagnosed Type 2 Diabetes.

Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.

Early intensive insulin therapy in patients with type 2 diabetes

1032-P: Time-in-Range during Short-Term Intensive Insulin Therapy Is Associated with Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes

[The Effects of Early Intensive Therapy on Islet Beta Cell Function and Long-Term Glycemia Control in Newly Diagnosed Type 2 Diabetic Patients with Different Fasting Plasma Glucose Levels.].

[Insulin Regimes and Impact on Glycemic Control in Patients with Type 1 Diabetes].

Effect of short-term intensive insulin therapy on α-cell function in patients with newly diagnosed type 2 diabetes.

Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel

Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update

Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.

Advantages and Disadvantages of Intensive Diabetes Therapy

Effect of Intensive Insulin Therapy on Β-Cell Function and Glycaemic Control in Patients with Newly Diagnosed Type 2 Diabetes: a Multicentre Randomised Parallel-Group Trial

Intensive glycemic control and renal outcome.

Glycemic Variability and Its Responses to Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes.

The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery

Blood sugar control in the intensive care unit: time to relook

[Unmet needs in the therapy of type 2 diabetes mellitus. How can barriers to insulin therapy be overcome?]

Individualized Glycemic Management of the Patients in Intensive Care Units